Areas where scientific evidence is lacking or incomplete.
Positive results concentrate in manufacturer-affiliated research; independent trials are lacking.
Implications: Cochrane rates certainty low to very low precisely because of this non-independence.
Little data beyond 6 months to 3 years.
Implications: Lasting efficacy and safety in chronic conditions like Alzheimer's or TBI are unestablished.
No clinical studies test whether it prevents dementia or slows decline in healthy people.
Implications: Off-label nootropic use has no clinical support for prevention.
As a peptide mixture, no single half-life can be defined.
Implications: BBB penetration is suggested preclinically but poorly confirmed in humans after IV infusion.
Beyond mixing incompatibilities, systemic interactions are not well studied.
Implications: Interactions with common regimens remain largely unknown.
Trials focus on clinical scales (NIHSS, MMSE), not well-being or caregiver burden.
Implications: Patient-centred outcomes are largely missing from the evidence base.
APOE4 effect is mixed; optimal TBI subgroups are undefined.
Implications: Cannot yet say who benefits most or whether genotype changes response.
No human data in pregnancy or breastfeeding.
Implications: Use not recommended despite non-teratogenic animal findings.
Little detail on standardised monitoring for porcine-tissue contamination.
Implications: The contamination risk is acknowledged but its surveillance is under-described.
Expert disagreements and competing evidence.
Industry-affiliated meta-analyses show improved NIHSS and a favourable survival signal in severe stroke.
Bornstein meta-analysis: improved NIHSS, mortality signal in severe subgroups.
Cochrane reviews (2010, 2020, 2023) find no benefit on all-cause death and insufficient evidence on function or quality of life.
Independent pooled RCTs, low to very low certainty.
Verdict Note
Industry meta-analyses show NIHSS gains; independent Cochrane reviews find no mortality or functional benefit.
Manufacturer and many trials call it safe and well-tolerated, with adverse-event rates near placebo.
Industry trial tolerability data.
The 2023 Cochrane update found a significant increase in non-fatal serious adverse events (RR 2.39).
Pooled independent RCTs; RR 2.87 at the 30 mL dose.
Verdict Note
The independent SAE signal contradicts the well-tolerated framing.
The CAPTAIN series reported improvement across a 14-scale ensemble in moderate-to-severe TBI.
CAPTAIN multidimensional analysis.
A three-arm RCT found no significant difference in primary cognitive outcomes; CAPTAIN narrowly missed significance in ITT.
Independent RCT and ITT re-reading.
Verdict Note
Positive ensemble signals narrowly miss significance in ITT analyses.
Industry trials report significant ADAS-cog and global function improvement in vascular and Alzheimer's dementia.
Industry-sponsored cognitive-scale data.
Cochrane describes the vascular-dementia evidence as weak and very low quality, with modest, possibly non-meaningful benefit.
Independent quality appraisal.
Verdict Note
Statistical gains exist; real-world significance is doubted by reviewers.
Non-carriers were three times more likely to respond in one four-month trial.
Responder analysis by genotype.
A different RCT found greater BDNF increases specifically in APOE4 carriers.
BDNF biomarker trial.
Verdict Note
Opposite findings on carriers vs non-carriers.
A retrospective review reported lower mortality in poor-grade SAH.
Retrospective poor-grade cohort.
An observational study found no mortality effect without neuromonitoring; the CESAR pilot was neutral at 6 months.
Observational + CESAR pilot.
Verdict Note
Benefit appears only with neuromonitoring; pilot RCT was neutral.